Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 497Neoplasms 302Breast Neoplasms 294Colorectal Neoplasms 228Neoplasm Metastasis 194Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 159Multiple Myeloma 158Recurrence 131Melanoma 125Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 104Stomach Neoplasms 102Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 84Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

belzutifan 3palbociclib 1lenvatinib 1cabozantinib 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × von Hippel-Lindau Disease × 90 days × Clear all
NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting
450 enrolled
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2026-04-13

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting
50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡